NAS10026,906−5.38%S&P7,400−3.75%GOLD$4,127+1.33%BTC$76,159−5.28%VIX24.13+45.27%latest tape · as of 20:03 UTC
The Screen · Industrials · Specialty Business Services
Rentokil Initial plc
RTO · the NYSE · USD · Market cap $12.2B · 63,388 employees
Rentokil Initial plc, together with its subsidiaries, provides route-based services in North America, Europe, the United Kingdom, Asia, the Middle East, North Africa, Turkey, and Pacific.
FAIL · Does not pass the screen
24.17 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price24.17 USD at the 4 Nov 2026 close
Our value readUndervalued vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.01, read 2026-11-02
Ethical does not pass the values gate
Price24.17 USD
Fair value30.20
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-28Read Markup21.21+14.0% to today ✓Markdown gives way to Markup after a 5% slide in 7 weeks
2026-09-12Read Markdown22.37+8.0% to today Distribution gives way to Markdown after a 9% slide in 4 weeks
2026-08-12Read Distribution24.46-1.2% to today ✓Markdown gives way to Distribution after a 20% slide in 6 weeks
2026-07-02Read Markdown30.66-21.2% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Rentokil Initial plc holds its Markup at $24.17. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$24.17
Valuation
38.98 trailing · 16.41 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.47
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
42.47%
Below 33%
Interest-bearing debt is 42.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.01%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
24.04%
Below 49%
Money owed to the company is 24.0% of assets, under the 49% limit.
Pass
Revenue purity
0.45%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Rentokil Initial's business is in a permissible area, but its interest-bearing debt is about 42% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RTO's ethical verdict changes
Today RTO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 20% discount to our $30.20 fair value, 6.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 20.0% discount to the base estimate.
Where our models see it going: fair-value estimate $30.20, with a range of $23.31 to $36.82, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pest routes that fail to excite
Think of the van that turns up at your office or home every few months to keep the mice and wasps at bay. That steady, unglamorous work is exactly what Rentokil Initial does across dozens of countries. The service feels essential yet the numbers show only 6 percent revenue growth, a 7 percent profit margin and a 5 percent return on equity.
We pass on the shares. The stock trades at 18.5 times forward earnings with a 15 percent gap to our fair value, but the low returns and unknown competitive edge leave no real margin of safety once you strip away the analyst buy ratings. Ethical screens are cleared, yet that alone does not create an opportunity.
The main risk is that modest growth and thin returns persist in a business where pricing power looks limited and costs can creep up with fuel and labour. A cyclical slowdown in commercial real estate would hit volumes quickly. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RTO trades on the NYSE (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$23.57+11.1%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-10-28Markup · changed$21.21+0.0%Entry 9
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-10-21Markdown$21.21+4.8%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-10-14Markdown$20.24+2.2%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-10-02Markdown$19.80-11.5%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-09-12Markdown · changed$22.37-8.5%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-07-18Markdown$30.66+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (4 analysts) rates it none, with a mean price target of $36.
2026-07-03Markdown$30.66+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$30.66Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
